In denying the eighth citizen petition filed by Teva Pharmaceutical Industries Ltd. to protect its blockbuster multiple sclerosis (MS) drug Copaxone from generic competition, the FDA followed a hard and fast regulatory line distinguishing complex nonbiologics from biologics.